12 July 2018

My name is Anglita Yanti Setiasti, Indonesian nationality, currently working as a PhD candidate at the Dept. of Urology, theme Urological cancer.

When you were a kid what did you want to be when you grew up? Can you tell us something about your child years. 

Wanna be a medical-doctor (I got this :D ) or stewardess (but not this one :D ).

What was your previous academic training, where did you study and why that study? 

I did my pathologic residency and became a pathologist at  Faculty of Medicine Padjadjaran University, Bandung, Indonesia and graduated as MSc from the same university afterward. I love the art of the medicine by helping people finding out the puzzle behind their disease, in pathology the combination of knowledge-research-medical practise is concised together.

The RIMLS motto is: ‘Today’s molecules for tomorrow’s medicine’. What does this mean for you? 

This means long-life learning always promising and open the sky for any possibilities for the greatness of patient care  and humanity. There is always hope!

Who is your great example as scientists? And please give a motivation why.

Avicenna. Because he proved that the scientific world could be explain reasonably and logically related to God’s creation.

Given unlimited finance what experiment would you perform?

Cancer treatment, especially breast cancer because its really emerging in my country Indonesia. It would help and save many women and families related to her.

What does your working area (desk, office) look like and what does it say about you (or your research)?

My lab where I am working now is so nice and friendly, we care about each other also professional in our work. Since the very beginning I did feel they accept me with warm hearted so I’ve been happy and working enjoyably till today, even though I was very far far away from my home-country. I love to work in a simple, friendly and clean environment, I always try to keep my space/desk clean and tidy.

Nominate a colleague to be in the spotlight and what would you like to ask him or her?

Rebecca Halbach. What is the one that I hate the most?

What type of person are you, quick insights:

a) Mac or PC?                                : Absolutely Mac!!
b) Theater or cinema?                 : Cinema
c) Dine out or dine in?                 : Dine out somehow
d) Ferrari or Fiat?                         : Hhmmm... probably Fiat
e) Shopaholic or chocoholic?     :  Neither both
f) Culture or Nature                     : Culture

Related news items

Biomarkers found in COVID-19 patients support bradykinin hypothesis

29 May 2020

A study into inflammatory substances in the blood of COVID-19 patients supports the hypothesis that kinins could play a role in the respiratory problems experienced by critically ill COVID-19 patients in IC. This discovery, published at MedRxiv, could lead to the development of new treatments.

read more

Introducing OnePlanet Research Center webinar 5 June, 16:00 hrs.

29 May 2020

OnePlanet Research Center develops digital technologies to create a society in which everyone can live a healthy life and has access to healthy and sustainable food. Radboudumc and Radboud University are amongst the founding partners. Find out what OnePlanet can do for you in this online session.

read more

Terrestrial bacteria can grow on nutrients from space

26 May 2020

Researchers from the Radboudumc describe in an article in Astrobiology that bacteria can survive on an 'extraterrestrial diet', which affected their pathogenic potential.

read more

The new front line: big data podcast

22 May 2020

What role do big data and technology play in the fight against corona? What data can help save lives? How do you ensure that your personal health data is used safely? Among others, Peter-Bram 't Hoen explains.

read more

OARSI Basic Science Award for Peter van der Kraan

22 May 2020

Purpose of this Basic Science Award of the Osteoarthritis Research Society International (OARSI) is to stimulate fundamental research in the field of osteoarthritis. Congratulations Peter.

read more

First clinical trial with genetically modified malaria vaccine completed

22 May 2020

In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.

read more